Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aeglea Bio Therapeutics stock
Learn how to easily invest in Aeglea Bio Therapeutics stock.
Aeglea Bio Therapeutics Inc is a biotechnology business based in the US. Aeglea Bio Therapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea Bio Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aeglea Bio Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AGLE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aeglea Bio Therapeutics stock price (NASDAQ: AGLE)Use our graph to track the performance of AGLE stocks over time.
Aeglea Bio Therapeutics shares at a glance
|Latest market close||$0.55|
|52-week range||$0.59 - $8.50|
|50-day moving average||$1.32|
|200-day moving average||$4.11|
|Wall St. target price||$4.43|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.09|
Buy Aeglea Bio Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aeglea Bio Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aeglea Bio Therapeutics price performance over time
|1 week (2022-06-20)||N/A|
|1 month (2022-05-31)||-65.47%|
|3 months (2022-03-28)||N/A|
|6 months (2021-12-31)||-88.52%|
|1 year (2021-07-01)||-92.35%|
|2 years (2020-07-01)||-94.15%|
|3 years (2019-07-01)||6.84|
|5 years (2017-06-30)||3.85|
Aeglea Bio Therapeutics financials
|Revenue TTM||$20.1 million|
|Gross profit TTM||$-38,330,000|
|Return on assets TTM||-36.41%|
|Return on equity TTM||-77.69%|
|Market capitalisation||$39.2 million|
TTM: trailing 12 months
Aeglea Bio Therapeutics share dividends
We're not expecting Aeglea Bio Therapeutics to pay a dividend over the next 12 months.
Aeglea Bio Therapeutics share price volatility
Over the last 12 months, Aeglea Bio Therapeutics's shares have ranged in value from as little as $0.585 up to $8.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea Bio Therapeutics's is 1.5957. This would suggest that Aeglea Bio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea Bio Therapeutics overview
Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.
Aeglea Bio Therapeutics in the news
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
Kezar (KZR) Doubles on Promising Kidney Disorder Study Data
Frequently asked questionsWhat percentage of Aeglea Bio Therapeutics is owned by insiders or institutions?
Currently 2.004% of Aeglea Bio Therapeutics shares are held by insiders and 73.816% by institutions. How many people work for Aeglea Bio Therapeutics?
Latest data suggests 99 work at Aeglea Bio Therapeutics. When does the fiscal year end for Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics's fiscal year ends in December. Where is Aeglea Bio Therapeutics based?
Aeglea Bio Therapeutics's address is: 805 Las Cimas Parkway, Austin, TX, United States, 78746 What is Aeglea Bio Therapeutics's ISIN number?
Aeglea Bio Therapeutics's international securities identification number is: US00773J1034 What is Aeglea Bio Therapeutics's CUSIP number?
Aeglea Bio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00773J103
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert